Genmab A (GMAB) Cost of Revenue (2018 - 2026)

Genmab A (GMAB) has reported Cost of Revenue for 9 consecutive years, with $84.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 15.15% year-over-year to $84.0 million; the trailing twelve-month figure through Jun 2026 stood at $405.0 million (up 6.86% YoY), and the FY2025 full-year result was $238.0 million, up 66.43% from the prior year.
• Cost of Revenue improved to $84.0 million in Q2 2026 per GMAB's latest filing, from $65.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $157.0 million in Q3 2025 and bottomed at $91450.9 in Q4 2022.
• Historically, Cost of Revenue has averaged $60.2 million across 5 years, with a median of $55.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue sank 99.99% in 2022, then soared 35984.93% in 2023.
• Over 5 years, Cost of Revenue stood at $91450.9 in 2022, then jumped by 35984.93% to $33.0 million in 2023, then soared by 333.33% to $143.0 million in 2024, then rose by 9.79% to $157.0 million in 2025, then slumped by 46.5% to $84.0 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $84.0 million, $65.0 million, and $157.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.